Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder
worldwide. Clinically, it is characterized by a progressive degeneration of dopaminergic …

Parkinson's disease (PD) is a progressive neurodegenerative disorder. The classical
behavioral defects of PD patients involve motor symptoms such as bradykinesia, tremor, and …

The pathogenesis of Parkinson's disease (PD) is closely interwoven with the process of
aging. Moreover, increasing evidence from human postmortem studies and from animal …

Parkinson's disease (PD) is characterised by the progressive loss of midbrain dopaminergic
neurons and the presence of aggregated α-synuclein (α-syn). Pericytes and microglia, two …

Proinflammatory markers were found in brains of Parkinson's disease (PD) patients. After
years of L-Dopa symptomatic treatment, most PD patients develop dyskinesias. The …

Parkinson's disease (PD) is a neurodegenerative disorder often associated with pre-motor
symptoms involving both gastrointestinal and olfactory tissues. PD patients frequently suffer …

Among the pathological events associated with the dopaminergic neurodegeneration
characteristic of Parkinson's disease (PD) are the accumulation of toxic forms of α-synuclein …

Background Increasing evidence suggests that alpha‐synuclein (αSyn) accumulation in
cholinergic and adrenergic fibers in the skin is a useful biomarker to diagnose idiopathic …

Background Preclinical rodent models of Parkinson's aim to recapitulate some of the
hallmarks of the disease as it presents in humans, including the progressive neuronal loss of …

Glucose is a major energy source for the brain, necessary to preserve proper
neurophysiological functions; aberrant glucose metabolism in the brain has been …